Crossmark

Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial

Crossref DOI link: https://doi.org/10.1007/s13300-021-01083-1

Published Online: 2021-05-26

Published Print: 2021-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sorice, Gian Pio https://orcid.org/0000-0001-9489-1534
Cinti, Francesca https://orcid.org/0000-0001-5170-7055
Leccisotti, Lucia https://orcid.org/0000-0002-6000-2898
D’Amario, Domenico https://orcid.org/0000-0003-3774-8330
Lorusso, Margherita https://orcid.org/0000-0002-7867-2777
Guzzardi, Maria Angela https://orcid.org/0000-0001-9574-5088
Mezza, Teresa https://orcid.org/0000-0001-5407-9576
Cocchi, Camilla https://orcid.org/0000-0002-4355-6194
Capece, Umberto https://orcid.org/0000-0001-8048-8664
Ferraro, Pietro Manuel https://orcid.org/0000-0002-1379-022X
Crea, Filippo https://orcid.org/0000-0001-9404-8846
Giordano, Alessandro https://orcid.org/0000-0002-6978-0880
Iozzo, Patricia https://orcid.org/0000-0001-6443-7074
Giaccari, Andrea https://orcid.org/0000-0002-7462-7792
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03313752 at ClinicalTrials.gov

Documents that mention this clinical trial

Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial
https://doi.org/10.1007/s13300-021-01083-1

Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes
https://doi.org/10.1186/s12933-023-02091-0
License Information

Text and Data Mining valid from 2021-05-26

Version of Record valid from 2021-05-26
More Information

Article History

Received: 9 April 2021

Accepted: 12 May 2021

First Online: 26 May 2021